SAB Biotherapeutics, Inc. (SABS)

NCM – Real vaqt narxi. Valyuta: USD

3.79

+0.03 (0.66%)

Bozor ochiq: Aug 12, 2026, 11:52 AM EDT

3.77

+0.01 (0.27%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

07.08.2026

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics NASDAQ: SABS said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.

06.08.2026

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE ‑ hATG study of SAB ‑ 142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis Operational runway through 2028 to support SAFEGUARD study, PRISE-hATG study and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and provided business highlights. “The second quarter was marked by strong execution as we advanced SAB-142 across key clinical and operational milestones.

Videolar

No Data

There is no data to display

SAB Biotherapeutics, Inc. (SABS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Videolar

No Data

Press-relizlar

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Videolar

No Data

Press-relizlar

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Search stocks

SAB Biotherapeutics, Inc. (SABS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Videolar

No Data

Press-relizlar

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

Videolar

No Data

Press-relizlar

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights